Specific modulation of the anti-DNA autoantibody–nucleic acids interaction by the high affinity RNA aptamer

Kim, Young-Mee; Choi, Kang Hyun; Jang, Young-Ju; Yu, Jaehoon; Jeong, Sunjoo

doi:10.1016/s0006-291x(02)02858-9

Cited by 20 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While early efforts focused largely on nucleic acid-binding targets (e.g. Bock et al, 1992;Green et al, 1995;Jellinek et al, 1994Jellinek et al, , 1995Pagratis et al, 1997;Ruckman et al, 1998), subsequent applications have included a wide variety of proteins, including selectins (O'Connell Wiegand et al, 1996 mAb198 (anti-AChR antibody) 6 nmol/L Lee and Sullenger, 1997 mAb G6-9 (anti-DNA antibody) 2 nmol/L Kim et al, 2003 mAb 20 (anti-insulin receptor antibody) 30 nmol/L Lee and Sullenger, 1996 Viral proteins HIV-RT 25 pmol/L Kensch et al, 2000;Tuerk et al, 1992 HIV Rev 1 nmol/L Tuerk and MacDougal-Waugh, 1993 HIV Tat ND Tuerk and MacDougal-Waugh, 1993 HIV gp120 5 nmol/L Khati et al, 2003 HIV integrase 10 nmol/L Allen et al, 1995 HCV NS5B 1.5 nmol/L Biroccio et al, 2002 Coagulation cascade components Thrombin 0.5 nmol/L-200 nmol/L Bock et al, 1992;Tasset et al, 1997 Factor VIIa 11 nmol/L Rusconi et al, 2000 Factor IXa 600 pmol/L Rusconi et al, 2002 Activated protein C 110 nmol/L Gal et al, 1998 Signaling mediators Bock et al, 1992;Green et al, 1995;Jellinek et al, 1994Jellinek et al, , 1995Pagratis et al, 1997;Ruckman et al, 1998), subsequent applications have included a wide variety of proteins, including selectins (O'Connell Wiegand et al, 1996 mAb198 (anti-AChR antibody) 6 nmol/L Lee and Sullenger, 1997 mAb G6-9 (anti-DNA antibody) 2 nmol/L Kim et al, 2003 mAb 20 (anti-insulin receptor antibody) 30 nmol/L Lee and Sullenger, 1996 Viral proteins HIV-RT 25 pmol/L Kensch et al, 2000;Tuerk et al, 1992 HIV Rev 1 nmol/L …”

Section: Aptamer Targetsmentioning

confidence: 99%

Properties of Therapeutic Aptamers

Cload

McCauley

Keefe

et al. 2006

The Aptamer Handbook

View full text Add to dashboard Cite

Since the invention of the SELEX process and the isolation of the first protein-specific aptamers, parallels to the functional properties of monoclonal antibodies have been drawn. While antibodies have demonstrated utility in a number of settings, their development as therapeutic agents has been long and difficult and it is only in the last 5 years that the field has matured to the stage where one can point to a number of unqualified clinical successes. In many respects, the opportunities for aptamers as therapeutics continue to parallel those for antibodies although the technical challenges have been somewhat different. 2004 was a milestone year for the field with the US Food and Drug Administration (FDA) approval of pegaptanib (Macugenä). In this chapter, we review the properties of aptamers as druglike molecules, highlighting their functional capabilities as target-specific binding agents and our current understanding of how aptamers behave in vivo with respect to distribution, metabolism, and tolerability. The antibody experience provides important lessons for the development of aptamer therapeutics and points the way for future applications which will particularly favor progress with aptamers. Aptamer TargetsThe collected experience of both academic and industry research suggests that aptamers are capable of binding to targets from virtually any protein class (Sullenger and Gilboa, 2002). While early efforts focused largely on nucleic acid-binding targets (e.g.

show abstract

Section: Aptamer Targetsmentioning

confidence: 99%

Properties of Therapeutic Aptamers

Cload

McCauley

Keefe

et al. 2006

The Aptamer Handbook

View full text Add to dashboard Cite

show abstract

“…Anti-DNA autoantibodies against single-or double-stranded DNA react with self-antigen to produce immune complexes and mediate dysfunction of various organs, including the skin, joint, kidneys (serious glomerular kidney damage), and serosal membranes [49]. Current therapies for SLE include immunosuppressants, cytotoxic agents for reducing autoantibody production, and glucocorticoid (corticosteroids) for reducing inflammation.…”

Section: Aptamers For Slementioning

confidence: 99%

“…An RNA aptamer with a higher binding affinity to G6-9 has been developed. This aptamer may be developed for the diagnosis and treatment of SLE [49].…”

Section: Aptamers For Slementioning

confidence: 99%

See 1 more Smart Citation

Aptamer Oligonucleotides: Novel Potential Therapeutic Agents in Autoimmune Disease

Lan

2015

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

Aptamers are single-stranded deoxyribonucleic acid or ribonucleic acid oligonucleotides generated in vitro based on affinity for certain target molecules by a process known as Systematic Evolution of Ligands by Exponential Enrichment. Aptamers can bind their target molecules with high specificity and selectivity by means of structure compatibility, stacking of aromatic rings, electrostatic and van der Waals interactions, and hydrogen bonding. With several advantages over monoclonal antibodies and other conventional small-molecule therapeutics, such as high specificity and affinity, negligible batch to batch variation, flexible modification and stability, lack of toxicity and low immunogenicity, aptamers are becoming promising novel diagnostic and therapeutic agents. This review focuses on the development of aptamers as potential therapeutics for autoimmune diseases, including diabetes mellitus, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus.

show abstract

“…Unlike antibodies, aptamers can fold properly and retain activity in the intracellular environment. However, the majority of aptamers with potential therapeutic utility selected to date target extracellular proteins (Chen et al, 2003;Eyetech Study Group, 2002, 2003Green et al, 1995;Kim et al, 2003;Liu et al, 2009;Lupold et Fig. 9.…”

Section: Point Mutations and Anti-gp120 Aptamersmentioning

confidence: 99%